Project Grant R21AG091143
- Federal Grant Award Summary The University of Pennsylvania received a $6.72 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 15, 2025, with a completion date of August 31, 2029. This research initiative focuses on developing short RNA therapeutics designed to combat TDP-43 proteinopathy, a pathological hallmark affecting multiple neurodegenerative disorders including amyotrophic lateral sclerosis (ALS),...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded the University of Pennsylvania a $425,235 Project Grant effective February 1, 2026, through January 31, 2028, under the Aging Research program (CFDA 93.866). This research initiative, conducted at the University of Pennsylvania in Philadelphia, investigates antigen-specific CD8+ T cells in frontotemporal dementia (FTD), a neurodegenerative disorder characterized by progressive frontal and temporal lobe atrophy. The study...
- Federal Project Grant Award Summary The University of Pennsylvania received a $427,919 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded August 15, 2025, with a completion date of July 31, 2027. The award funds the development of integrated micro-to-macro network models to characterize disease spread patterns in frontotemporal dementia (FTD), specifically to distinguish between tau-related (FTLD-TAU) and TDP-43-related (FTLD-TDP)...
- Federal Project Grant Award Summary The University of Pennsylvania received a $2.71M Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective September 5, 2025, with completion scheduled for August 31, 2029. This research project will investigate the role of TRIM11 protein in regulating transactive response DNA-binding protein 43 (TDP-43) and...
- Federal Grant Award Summary The University of Pennsylvania received a $446,875 Project Grant award from the National Institute on Aging (Aging Research program, CFDA 93.866) effective September 1, 2025, through August 31, 2027. The award funds research investigating the genetic and molecular mechanisms of cellular senescence using the Drosophila (fruit fly) brain as a model system. The research aims to identify genes that, when knocked down in neurons or glial cells, modulate the onset and...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $805,573 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective September 15, 2025, with completion targeted for June 30, 2030. This award supports innovative research investigating the role of N6-methyladenosine (M6A) RNA modifications in Alzheimer's disease and related tauopathies. The research deliverables include comprehensive...
- Federal Grant Award Summary The University of Florida Division of Sponsored Research received a $419,375 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective June 1, 2025, through May 31, 2026. The award supports research investigating the pathological implications of tau-ribonucleic acid (RNA) interactions in tauopathies, particularly Alzheimer's disease (AD). The project aims to identify and characterize RNA motifs that bind...
- Grant Award Summary The National Institute on Aging awarded the University of South Florida a Project Grant totaling $3,297,926 under the Aging Research program (CFDA 93.866) for the period September 1, 2025, through August 31, 2029. The research focuses on developing novel peptidomimetic biomaterials designed to inhibit amyloid-beta (Aβ42) aggregation in Alzheimer's disease. The grant supports the advancement of a lead compound that stabilizes the helical conformation of amyloid-beta...
- Federal Project Grant Award Summary Duke University's Office of Research Administration is conducting a five-year research project funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), with $493,972 obligated for the project period spanning January 1, 2026, through December 31, 2030. The project, titled "Cell Type-Specific Epitranscriptomic Regulation in the Brain in Aging and Alzheimer's Disease," focuses on understanding how adenosine methylation...
- Federal Grant Award Summary The National Institute on Aging awarded a $162,000 Project Grant to The Washington University (Office of Sponsored Research Services) under the Aging Research program (CFDA 93.866) for the period March 1, 2026, through February 28, 2029. The award supports research to identify and characterize novel therapy targets in TDP-43 proteinopathies—a class of neurodegenerative diseases characterized by aberrant nuclear clearance and cytoplasmic aggregation of TAR...
The National Institute on Aging awarded the University of Pennsylvania a Project Grant of $446,875.00 under the Aging Research program (CFDA 93.866) to develop and characterize short RNA therapeutics targeting TAF15 (TATA-binding protein associated factor 15) phase transitions in frontotemporal dementia and Alzheimer's disease-related dementias. The research will define short ribonucleic acids (approximately 25-34 nucleotides) capable of antagonizing pathological phase transitions of TAF15, an RNA-binding protein with a prion-like domain that misfolds in approximately 10 percent of frontotemporal dementia cases. The award period extends from March 15, 2026 through February 29, 2028. This project builds upon the institution's prior success developing similar short RNA antagonists for related proteins (TDP-43 and FUS) and aims to generate therapeutic agents that prevent aberrant TAF15 aggregation, reverse existing fibril formation, and restore nuclear localization of the protein in degenerating neurons. The deliverables include preclinical research findings, validated short RNA sequences, mechanism of action data, and supporting evidence of efficacy in human neuronal models. The research outcomes are intended to advance therapeutic options for fatal neurodegenerative disorders currently lacking effective treatments.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $446.9k | 3/13/26 |